{'fraction_non_alphanumeric': 0.013959390862944163, 'fraction_numerical': 0.0, 'mean_word_length': 5.362903225806452, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Strategic groupings of US biotechnology initial public offerings and a measure of their market influence

This study verifies the existence of strategic groups among biotechnology firms that have filed for an initial public offering (IPO). We found three distinct groupings based on the dimensions of competitive scope and growth. Differences also exist between these groupings and an aspect of market influence – the ability to attract strategic partners. We found that biotechnology IPOs that seek greater breadth in competitive scope and growths also have more alliance partners. This paper adds to our knowledge of the bio-pharmaceutical market-sector and the strategic intentions of firms in an emerging, disruptive industry and their ability to attract strategic coalition partners.